In recent years huge progress has been achieved in the development of MCL-1-specific BH3-mimetics with five independent compounds currently undergoing clinical evaluation in hematologic malignancies, and recruitment is underway for a further clinical trial in solid tumors, including breast cancer (NCT04837677) (Table 1). This evidence concerns the gene MCL1 and hematologic disorder.